Is Travere Therapeutics Stock a Good Investment?
Travere Therapeutics Investment Advice | TVTX |
- Examine Travere Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Travere Therapeutics' leadership team and their track record. Good management can help Travere Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Travere Therapeutics' business and its evolving consumer preferences.
- Compare Travere Therapeutics' performance and market position to its competitors. Analyze how Travere Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Travere Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Travere Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Travere Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Travere Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Travere Therapeutics Stock
Researching Travere Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.07. Travere Therapeutics had not issued any dividends in recent years. The entity had 1:9 split on the 8th of November 2011.
To determine if Travere Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Travere Therapeutics' research are outlined below:
| Travere Therapeutics had very high historical volatility over the last 90 days | |
| Travere Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 233.18 M. Net Loss for the year was (320.63 M) with profit before overhead, payroll, taxes, and interest of 7.93 M. | |
| Travere Therapeutics currently holds about 553.17 M in cash with (237.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Acquisition by Eric Dube of 260000 shares of Travere Therapeutics at 20.46 subject to Rule 16b-3 |
Travere Therapeutics Quarterly Good Will |
|
Travere Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Travere Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Travere Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Travere Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Travere Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-05-04 | 2017-03-31 | -0.26 | -0.29 | -0.03 | 11 | ||
2017-03-01 | 2016-12-31 | -0.26 | -0.23 | 0.03 | 11 | ||
2020-11-05 | 2020-09-30 | -0.52 | -0.44 | 0.08 | 15 | ||
2025-02-13 | 2024-12-31 | -0.3786 | -0.47 | -0.0914 | 24 | ||
2017-08-09 | 2017-06-30 | -0.21 | -0.34 | -0.13 | 61 | ||
2016-08-04 | 2016-06-30 | -0.23 | -0.37 | -0.14 | 60 | ||
2016-02-25 | 2015-12-31 | -0.21 | -0.07 | 0.14 | 66 | ||
2022-01-10 | 2021-12-31 | -0.68 | -0.84 | -0.16 | 23 |
Travere Therapeutics Target Price Consensus
Travere target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Travere Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 15 | Strong Buy |
Most Travere analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Travere stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Travere Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTravere Therapeutics Target Price Projection
Travere Therapeutics' current and average target prices are 21.04 and 27.40, respectively. The current price of Travere Therapeutics is the price at which Travere Therapeutics is currently trading. On the other hand, Travere Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Travere Therapeutics Market Quote on 25th of March 2025
Target Price
Analyst Consensus On Travere Therapeutics Target Price
Travere Therapeutics Analyst Ratings
Travere Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Travere Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Travere Therapeutics' financials, market performance, and future outlook by experienced professionals. Travere Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Travere Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Travere Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Travere Therapeutics backward and forwards among themselves. Travere Therapeutics' institutional investor refers to the entity that pools money to purchase Travere Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 2.2 M | Emerald Advisers, Llc | 2024-12-31 | 2.1 M | Woodline Partners Lp | 2024-12-31 | 2.1 M | Geode Capital Management, Llc | 2024-12-31 | 1.8 M | Kynam Capital Management, Lp | 2024-12-31 | 1.8 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.7 M | Bank Of America Corp | 2024-12-31 | 1.3 M | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 1.2 M | Blackrock Inc | 2024-12-31 | 8 M | Armistice Capital, Llc | 2024-12-31 | 7.4 M |
Travere Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.89 B.Market Cap |
|
Travere Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.82) | (0.77) | |
| Return On Assets | (0.54) | (0.57) | |
| Return On Equity | (5.44) | (5.17) |
Determining Travere Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Travere Therapeutics is a good buy. For example, gross profit margin measures Travere Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Travere Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Travere Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Travere Therapeutics. Check Travere Therapeutics' Beneish M Score to see the likelihood of Travere Therapeutics' management manipulating its earnings.
Evaluate Travere Therapeutics' management efficiency
Travere Therapeutics has return on total asset (ROA) of (0.2315) % which means that it has lost $0.2315 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4675) %, meaning that it created substantial loss on money invested by shareholders. Travere Therapeutics' management efficiency ratios could be used to measure how well Travere Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2025. Return On Capital Employed is likely to rise to -0.77 in 2025. At this time, Travere Therapeutics' Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 138.4 M in 2025, whereas Total Assets are likely to drop slightly above 474.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.75 | 0.71 | |
| Tangible Book Value Per Share | (0.57) | (0.54) | |
| Enterprise Value Over EBITDA | (6.46) | (6.78) | |
| Price Book Value Ratio | 23.26 | 22.10 | |
| Enterprise Value Multiple | (6.46) | (6.78) | |
| Price Fair Value | 23.26 | 22.10 | |
| Enterprise Value | 1.7 B | 1.8 B |
Understanding the operational decisions made by Travere Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.751 |
Basic technical analysis of Travere Stock
As of the 25th of March, Travere Therapeutics has the Coefficient Of Variation of 1033.64, risk adjusted performance of 0.0949, and Semi Deviation of 2.98. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Travere Therapeutics, as well as the relationship between them.Travere Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Travere Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Travere Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Travere Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Travere Therapeutics' Outstanding Corporate Bonds
Travere Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Travere Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Travere bonds can be classified according to their maturity, which is the date when Travere Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| TRAVELERS PPTY CAS Corp BondUS89420GAE98 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Travere Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Travere Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0949 | |||
| Market Risk Adjusted Performance | 0.2045 | |||
| Mean Deviation | 2.95 | |||
| Semi Deviation | 2.98 | |||
| Downside Deviation | 3.17 | |||
| Coefficient Of Variation | 1033.64 | |||
| Standard Deviation | 3.8 | |||
| Variance | 14.44 | |||
| Information Ratio | 0.1037 | |||
| Jensen Alpha | 0.4248 | |||
| Total Risk Alpha | 0.5114 | |||
| Sortino Ratio | 0.1243 | |||
| Treynor Ratio | 0.1945 | |||
| Maximum Drawdown | 20.04 | |||
| Value At Risk | (4.94) | |||
| Potential Upside | 6.29 | |||
| Downside Variance | 10.05 | |||
| Semi Variance | 8.86 | |||
| Expected Short fall | (3.72) | |||
| Skewness | 0.4612 | |||
| Kurtosis | 0.8895 |
| Risk Adjusted Performance | 0.0949 | |||
| Market Risk Adjusted Performance | 0.2045 | |||
| Mean Deviation | 2.95 | |||
| Semi Deviation | 2.98 | |||
| Downside Deviation | 3.17 | |||
| Coefficient Of Variation | 1033.64 | |||
| Standard Deviation | 3.8 | |||
| Variance | 14.44 | |||
| Information Ratio | 0.1037 | |||
| Jensen Alpha | 0.4248 | |||
| Total Risk Alpha | 0.5114 | |||
| Sortino Ratio | 0.1243 | |||
| Treynor Ratio | 0.1945 | |||
| Maximum Drawdown | 20.04 | |||
| Value At Risk | (4.94) | |||
| Potential Upside | 6.29 | |||
| Downside Variance | 10.05 | |||
| Semi Variance | 8.86 | |||
| Expected Short fall | (3.72) | |||
| Skewness | 0.4612 | |||
| Kurtosis | 0.8895 |
Consider Travere Therapeutics' intraday indicators
Travere Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Travere Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 21.04 | |||
| Day Typical Price | 21.04 | |||
| Price Action Indicator | (0.12) | |||
| Period Momentum Indicator | (0.25) | |||
| Relative Strength Index | 53.04 |
Travere Therapeutics Corporate Filings
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 21st of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 12th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Travere Stock media impact
Far too much social signal, news, headlines, and media speculation about Travere Therapeutics that are available to investors today. That information is available publicly through Travere media outlets and privately through word of mouth or via Travere internal channels. However, regardless of the origin, that massive amount of Travere data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Travere Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Travere Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Travere Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Travere Therapeutics alpha.
Travere Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Travere Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Travere Therapeutics Historical Investor Sentiment
Investor biases related to Travere Therapeutics' public news can be used to forecast risks associated with an investment in Travere. The trend in average sentiment can be used to explain how an investor holding Travere can time the market purely based on public headlines and social activities around Travere Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Travere Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Travere Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Travere Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Travere Therapeutics.
Travere Therapeutics Maximum Pain Price Across June 20th 2025 Option Contracts
Travere Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Travere Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Travere Therapeutics' options.
Travere Therapeutics Corporate Management
| Elizabeth JD | General VP | Profile | |
| Elizabeth Reed | General VP | Profile | |
| William Rote | Senior Development | Profile | |
| CFA CFA | Chief Officer | Profile | |
| Angela Giannantonio | Senior Resources | Profile | |
| Jula MD | Chief Officer | Profile | |
| Casey Logan | Chief Officer | Profile |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.